Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 18/20 | 0.57 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15963489 | 1.00 | MME (0.57) | MMEMMEL1 | |
| Hydrochloric Acid SCHEMBL1912641 | 0.99 | MME (0.56) | MMEMMEL1 | |
| Hydrochloric Acid SCHEMBL1912657 | 0.87 | MMEL1 (0.61) | MMEMMEL1 | |
| SCHEMBL18724851 | 0.85 | MME (0.55) | MME | |
| SCHEMBL16939241 | 0.85 | MME (0.55) | MME | |
| SCHEMBL19355078 | 0.84 | MME (0.62) | MME | |
| SCHEMBL8550914 | 0.83 | MME (0.52) | MMEMMEL1 | |
| SCHEMBL17965425 | 0.83 | MMEL1 (0.66) | MMEMMEL1 | |
| SCHEMBL18027486 | 0.83 | MME (0.53) | MME | |
| SCHEMBL16932424 | 0.82 | MME (0.48) | MMEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112963-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| EP-2956464-B1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | NOVARTIS AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20170015688-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-9480693-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2016-11-01 | — | — | US | disclosed |
| EP-2594557-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2594556-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| US-20150374726-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2015-12-31 | — | — | US | disclosed |
| EP-2956464-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | Novartis AG (CH) | 2015-12-23 | — | — | EP | disclosed |
| US-9163040-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014126979-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | NOVARTIS AG (CH) | 2014-08-21 | — | — | WO | disclosed |
| US-20140228323-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594557-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112963-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | MME, REN, ENPP1 | MME 1/4885MMEL1 995/4885 |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | MME 1/4885MMEL1 299/4885 |
| US-20150374726-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | MME, REN, ENPP1 | MME 1/4885MMEL1 995/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MME 1/4885MMEL1 299/4885 |
| US-20170015688-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | MME, REN, ENPP1 | MME 1/4885MMEL1 995/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885MMEL1 118/4885 |
| US-20140228323-A1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS | MME, REN, ENPP1 | MME 1/4885MMEL1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.